Description: The MJ7/18 monoclonal antibody reacts with the mouse CD105 molecule, also known as Endoglin. This 90 kDa disulfide-linked homodimer is expressed by vascular endothelial cells. It is suggested that CD105 functions in adhesion and embryonic angiogenesis. Applications Reported: This MJ7/18 antibody has been reported for use in flow cytometric analysis. Applications Tested: This MJ7/18 antibody has been tested by flow cytometric analysis of bEnd.3 cells. This can be used at less than or equal to 1 µg per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest. eFluor® 450 is an alternative to Pacific Blue®. eFluor® 450 emits at 445 nm and is excited with the Violet laser (405 nm). Please make sure that your instrument is capable of detecting this fluorochome. Excitation: 405 nm; Emission: 445 nm; Laser: Violet Laser. Filtration: 0.2 µm post-manufacturing filtered.CD105 or Endoglin is a Type I transmembrane protein, which is highly expressed on human vascular endothelial cells. It exists on an O- and N-glycosylated homodimer. Up regulation of endoglin expression has been demonstrated in tumor vasculature and proliferating cells, suggesting that it is a proliferation associated endothelial marker. CD105 binds to TGF beta 1 and 3 with high affinity but not to TGF beta 2.
|4° C, store in dark, DO NOT FREEZE!|
|PBS with 0.1% gelatin and 0.09% sodium azide; pH 7.2|
For Research Use Only.
The Fisher Scientific Encompass Program offers items which are not part of our distribution portfolio. These products typically do not have pictures or detailed descriptions. However, we are committed to improving your shopping experience. Please use the form below to provide feedback related to the content on this product.
Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.Ok